Biohaven Pharmaceutical announced that the FDA has granted the company Fast Track Designation for Biohaven’s product candidate trigriluzole (BHV-4157) for the potential treatment of Spinocerebellar Ataxia (SCA). Trigriluzole previously received Orphan Drug Designation from the FDA for the treatment of SCA in 2016. Biohaven is currently conducting a phase II/III clinical trial in patients with […]
The post FDA grants Biohaven’s trigriluzole Fast Track Designation appeared first on CenterWatch News Online.
Powered by WPeMatico